SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 87.19 |
Enterprise Value ($M) | 180.52 |
Book Value ($M) | -103.07 |
Book Value / Share | -1.63 |
Price / Book | -0.85 |
NCAV ($M) | -103.31 |
NCAV / Share | -1.64 |
Price / NCAV | -0.84 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -14.82 |
Return on Assets (ROA) | -1.82 |
Return on Equity (ROE) | n/a |
Liquidity (mrq) | |
---|---|
Quick Ratio | 0.49 |
Current Ratio | 0.49 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 17.25 |
Assets | 17.50 |
Liabilities | 120.56 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | -42.43 |
Net Income | -47.05 |
Earnings Per Share Basic And Diluted | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -41.77 |
Cash from Investing | 0.00 |
Cash from Financing | 31.23 |
(click for more detail) |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
36,141 | 125,774 | 28.73 | |
56,026 | 175,682 | 31.89 | |
25,660 | 72,430 | 35.43 | |
(click for more detail) |
Similar Companies | |
---|---|
FENC – Fennec Pharmaceuticals Inc. | FLGC – Flora Growth Corp. |
FTLF – FitLife Brands, Inc. | GDTC – CytoMed Therapeutics Limited |
GELS – Gelteq Limited |